Cannabis Germplasm 101: Panel Discussion
How can we overcome the lack of accessible germplasm resources and begin proper plant breeding programs in cannabis?
“Fear, to a great extent, is born of a story we tell ourselves, and so I chose to tell myself a different story from the one women are told. I decided I was safe. I was strong. I was brave.” ~Cheryl Strayed, Wild
Biosynthesis is not a new process in science, but its implementation in the cannabis industry is turning heads and beginning to reshape the traditional approach to cannabis production.
While the debate about cannabis and cancer has been ongoing for the better part of the legalization movement, one Northwestern pharmaceutical company is partnering with the University of Washington in hopes to provide the answer finally.
DNA sequencing helps millions of people every year learn of their ancestry, as well as, identify certain health risks based on their genetic code. But DNA for cannabis? One Canadian company is changing the future of cannabis.
As more and more people turn to marijuana for relief, it’s become clear the legalization of cannabis plant growing and the drug product has opened up a new industry—in fact, the market size of the marijuana business is expected to skyrocket and reach $55.8 billion by 2025.
There’s nothing a cannabis cultivator enjoys more than harvesting the dense, fragrant buds at the end of a successful grow. However, getting there takes a touch of finesse, as well as an understanding of basic plant biology. Getting the early parts of the growing process right is essential to reaping a dream yield.
Yona Levy is the CEO of Alvit Pharma, an Israeli-based company specializing in the development of pharma-grade cannabis products. With over 20 years of experience in business management and investment banking, Levy has brought his skills to the cannabis industry, and with the team at Alvit, they aim to lead the world in the standardization, optimization, and delivery of products alternative to smoking medicinal cannabis.
It's not uncommon these days to see former chemists and molecular biologists move from the pharmaceutical industry into cannabis. It's just a logical next step into a growing sector. But to see a former NASA funded scientist, like for Shellene Suemori, move into cannabis, is an interesting move.